These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18774467)

  • 1. Why does androgen deprivation enhance the results of radiation therapy?
    Wo JY; Zietman AL
    Urol Oncol; 2008; 26(5):522-9. PubMed ID: 18774467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone therapy and radiotherapy for intermediate risk prostate cancer.
    Lee I; Sandler H
    Semin Radiat Oncol; 2008 Jan; 18(1):7-14. PubMed ID: 18082583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The timing and extent of androgen deprivation therapy for prostate cancer: weighing the clinical evidence.
    Ginzburg S; Albertsen PC
    Endocrinol Metab Clin North Am; 2011 Sep; 40(3):615-23, ix. PubMed ID: 21889724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant hormonal deprivation in locally advanced prostate cancer: does it make sense?
    Schulman CC; Wildschutz TP
    Acta Urol Belg; 1996 May; 64(2):57-61. PubMed ID: 8701814
    [No Abstract]   [Full Text] [Related]  

  • 7. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer.
    Hennenfent BR
    Br J Urol; 1998 Jul; 82(1):166. PubMed ID: 9698691
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con.
    Paulson DF
    Urology; 1996 Oct; 48(4):539-40. PubMed ID: 8886056
    [No Abstract]   [Full Text] [Related]  

  • 9. The case for neoadjuvant androgen suppression before radiation therapy.
    Zietman AL
    Mol Urol; 2000; 4(3):203-8;discussion 215. PubMed ID: 11062375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?
    Fang LC; Merrick GS; Wallner KE
    Oncology (Williston Park); 2010 Aug; 24(9):790-6, 798. PubMed ID: 20923031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
    Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
    Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.
    D'Angelillo RM; Franco P; De Bari B; Fiorentino A; Arcangeli S; Alongi F
    Crit Rev Oncol Hematol; 2015 Feb; 93(2):136-48. PubMed ID: 25459667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer.
    Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapy after radical prostatectomy: clinical considerations.
    Mitra A; Khoo V
    Surg Oncol; 2009 Sep; 18(3):247-54. PubMed ID: 19285386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
    Sonpavde G; Palapattu GS
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):439-50. PubMed ID: 20214524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Approaches Prior To Radical Prostatectomy.
    Ryan ST; Patel DN; Parsons JK; McKay RR
    Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.